[Elsevier] Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial |
|
This post will be closed automatically in 2026-08-02 03:25
Best Answer
Yesterday 03:26
|
| |
post
reply
points
810
50
Molecular and cellular bases of trained immunity
10
An intelligent multimodal medical image registration using hybrid meta-heuristic optimization with transformer-based residual UNet
10
Extrusion of biopolymers for food applications
10
Learning discriminative prototypes: Adaptive relation-aware refinement and patch-level contextual feature reweighting for few-shot classification
10
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00349-1/abstract
